GCF20216

GCF20216 is an innovative small molecule formulation developed by Guangzhou Green Cross Pharmaceutical. It utilizes a lipid microsphere delivery system specifically designed for perioperative emergency management and critical care. As part of the company's GCF series, which focuses on formulation innovations (classified as Class 2 innovative drugs under Chinese regulatory standards), GCF20216 aims to optimize the delivery of its active pharmaceutical ingredient for acute clinical settings. The lipid microsphere technology is typically employed to enhance the stability, reduce injection-site irritation, or improve the pharmacokinetic profile of lipophilic drugs administered intravenously. The drug is currently in the preclinical research and IND-enabling stage.